TYK MEDICINES-B (02410) experienced a notable increase of nearly 5% during afternoon trading. At the time of writing, the stock was up 3.65%, trading at HK$13.06, with a turnover of HK$28.91 million. The upward movement follows the company's recent announcement that its investigational Class 1 new drug, TY-9591 tablets (Edotinib Mesylate Tablets), has been included in the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) priority review list. This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and present with central nervous system metastases. Inclusion in the priority review program signifies a comprehensive acceleration of the drug's evaluation process, potentially leading to an earlier market launch and providing a new treatment option for patients in China.